Department of Clinical Laboratory, Jiaozhou Central Hospital, Qingdao 266300, China.
Operation Room, Jiyang People's Hospital, Jinan 251400, China.
J Healthc Eng. 2022 Mar 23;2022:8401202. doi: 10.1155/2022/8401202. eCollection 2022.
The study is designed to investigate the therapeutic effect of Yiqi Yangyin Decoction combined with docetaxel on advanced ovarian cancer (OC) patients and the effects on serum markers VEGF, HE4, and CA125.
92 patients with advanced OC were grouped into the study group and control group. The control group was given the treatment of basic chemotherapy combined with docetaxel. The study group was added the treatment of Yiqi Yangyin Decoction on the basis of the control group. The short-term efficacy, adverse reactions, tumor markers, quality of life, 3-year survival, and T cell subsets of the two groups were observed.
Compared to the control group, the study group's incidence of adverse reactions was lower. VEGF, HE4, and CA125 in the study group were decreased more obviously. The levels of CD3, CD4, and CD4/CD8 were sharply higher in the study group, while CD8 was notably reduced. After treatment, the scores of physical health, social function, and mental health in the study group were notably higher than those in the control group. Compared with the control group, the 3-year survival rate of the study group was notably higher, and the therapeutic effect of the study group was obviously better.
The combination of Yiqi Yangyin Decoction and docetaxel can improve the body immunity and the therapeutic effect of advanced OC, decrease the incidence of adverse reactions, and prolong the survival time, with good safety and effectiveness.
本研究旨在探讨益气养阴汤联合多西他赛治疗晚期卵巢癌(OC)患者的疗效及其对血清标志物 VEGF、HE4 和 CA125 的影响。
将 92 例晚期 OC 患者分为研究组和对照组。对照组给予基础化疗联合多西他赛治疗,研究组在对照组基础上加用益气养阴汤治疗。观察两组近期疗效、不良反应、肿瘤标志物、生活质量、3 年生存率及 T 细胞亚群。
与对照组相比,研究组不良反应发生率较低。研究组 VEGF、HE4、CA125 下降更明显。研究组 CD3、CD4、CD4/CD8 水平明显升高,CD8 明显降低。治疗后,研究组生理健康、社会功能、心理健康评分明显高于对照组。与对照组相比,研究组 3 年生存率明显较高,治疗效果明显更好。
益气养阴汤联合多西他赛可提高晚期 OC 患者的机体免疫力和治疗效果,降低不良反应发生率,延长生存时间,且安全性和有效性较好。